Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643177 | 0.94 | TAAR1 (0.63) | TAAR1TDP1CYP4F2CYP4A11IDO1 | |
| SCHEMBL81535 | 0.82 | TAAR1 (0.59) | TAAR1CYP4F2CYP4A11IDO1AGXT | |
| SCHEMBL29979925 | 0.81 | TAAR1 (0.63) | TAAR1TDP1IDO1AGXTCYP1A2 | |
| SCHEMBL1513555 | 0.81 | TAAR1 (0.63) | TAAR1TDP1IDO1AGXTCYP1A2 | |
| SCHEMBL4399626 | 0.80 | TAAR1 (0.74) | TAAR1TDP1IDO1AGXTMAOB | |
| SCHEMBL1047547 | 0.80 | TAAR1 (0.57) | TAAR1CYP4F2CYP4A11IDO1AGXT | |
| Ammonia Solution, Strong SCHEMBL1766782 | 0.79 | TAAR1 (0.61) | TAAR1TDP1IDO1AGXTCYP1A2 | |
| SCHEMBL1045131 | 0.78 | TAAR1 (0.55) | TAAR1CYP4F2CYP4A11IDO1AGXT | |
| SCHEMBL3456345 | 0.78 | TAAR1 (0.55) | TAAR1CYP4F2CYP4A11IDO1AGXT | |
| Alcohol SCHEMBL6297380 | 0.78 | TAAR1 (0.46) | TAAR1IDO1AGXTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | TAAR1 4735/4885TDP1 1121/4885CYP4F2 2611/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | TAAR1 4612/4885TDP1 1395/4885CYP4F2 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.